764 related articles for article (PubMed ID: 21676622)
1. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C
J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622
[TBL] [Abstract][Full Text] [Related]
2. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
3. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
Abu-Id MH; Warnke PH; Gottschalk J; Springer I; Wiltfang J; Acil Y; Russo PA; Kreusch T
J Craniomaxillofac Surg; 2008 Mar; 36(2):95-103. PubMed ID: 18234504
[TBL] [Abstract][Full Text] [Related]
4. Avascular mandibular osteonecrosis in association with bisphosphonate therapy: a report on four patients.
Friedrich RE; Blake FA
Anticancer Res; 2007; 27(4A):1841-5. PubMed ID: 17649782
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
6. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ
J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
[TBL] [Abstract][Full Text] [Related]
7. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis.
Tennis P; Rothman KJ; Bohn RL; Tan H; Zavras A; Laskarides C; Calingaert B; Anthony MS
Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):810-7. PubMed ID: 22711458
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G
Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788
[TBL] [Abstract][Full Text] [Related]
9. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
10. Identification of Risk Factors for Bisphosphonate-Associated Atypical Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database.
Bejhed RS; Kharazmi M; Hallberg P
Ann Pharmacother; 2016 Aug; 50(8):616-24. PubMed ID: 27179251
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Vahtsevanos K; Kyrgidis A; Verrou E; Katodritou E; Triaridis S; Andreadis CG; Boukovinas I; Koloutsos GE; Teleioudis Z; Kitikidou K; Paraskevopoulos P; Zervas K; Antoniades K
J Clin Oncol; 2009 Nov; 27(32):5356-62. PubMed ID: 19805682
[TBL] [Abstract][Full Text] [Related]
12. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
O'Ryan FS; Khoury S; Liao W; Han MM; Hui RL; Baer D; Martin D; Liberty D; Lo JC
J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404
[TBL] [Abstract][Full Text] [Related]
13. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
Mavrokokki T; Cheng A; Stein B; Goss A
J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons.
Khan AA; Rios LP; Sándor GK; Khan N; Peters E; Rahman MO; Clokie CM; Dore E; Dubois S
J Rheumatol; 2011 Jul; 38(7):1396-402. PubMed ID: 21498483
[TBL] [Abstract][Full Text] [Related]
15. Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S.
Skrepnek GH; Seal B; Tangirala M; Jeffcoat MK; Watts NB; Hay JW
Gen Dent; 2010; 58(6):484-92; quiz 493-4. PubMed ID: 21062718
[TBL] [Abstract][Full Text] [Related]
16. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
Wutzl A; Eisenmenger G; Hoffmann M; Czerny C; Moser D; Pietschmann P; Ewers R; Baumann A
Wien Klin Wochenschr; 2006 Aug; 118(15-16):473-8. PubMed ID: 16957978
[TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients.
Favia G; Pilolli GP; Maiorano E
J Rheumatol; 2009 Dec; 36(12):2780-7. PubMed ID: 19884275
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced osteonecrosis of the jaw: the state of the art.
Fassio A; Bertoldo F; Idolazzi L; Viapiana O; Rossini M; Gatti D
Reumatismo; 2017 May; 69(1):9-15. PubMed ID: 28535616
[TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
Estilo CL; Van Poznak CH; Wiliams T; Bohle GC; Lwin PT; Zhou Q; Riedel ER; Carlson DL; Schoder H; Farooki A; Fornier M; Halpern JL; Tunick SJ; Huryn JM
Oncologist; 2008 Aug; 13(8):911-20. PubMed ID: 18695259
[TBL] [Abstract][Full Text] [Related]
20. Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: a pilot study.
Carmagnola D; Celestino S; Abati S
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):e10-5. PubMed ID: 18801674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]